KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Net Income (2020 - 2025)

Historic Net Income for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$162.3 million.

  • Recursion Pharmaceuticals' Net Income fell 6929.22% to -$162.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.5 million, marking a year-over-year decrease of 8942.19%. This contributed to the annual value of -$463.7 million for FY2024, which is 4133.16% down from last year.
  • Recursion Pharmaceuticals' Net Income amounted to -$162.3 million in Q3 2025, which was down 6929.22% from -$171.9 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Net Income's 5-year high stood at -$30.5 million during Q1 2021, with a 5-year trough of -$202.5 million in Q1 2025.
  • Moreover, its 5-year median value for Net Income was -$76.7 million (2023), whereas its average is -$92.5 million.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Net Income crashed by 15393.85% in 2021 and then soared by 612.38% in 2022.
  • Recursion Pharmaceuticals' Net Income (Quarter) stood at -$65.0 million in 2021, then rose by 6.12% to -$61.0 million in 2022, then tumbled by 52.5% to -$93.0 million in 2023, then tumbled by 92.38% to -$178.9 million in 2024, then grew by 9.31% to -$162.3 million in 2025.
  • Its last three reported values are -$162.3 million in Q3 2025, -$171.9 million for Q2 2025, and -$202.5 million during Q1 2025.